BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 32839252)

  • 1. Structural Optimization and Enhanced Prodrug-Mediated Delivery Overcomes Camptothecin Resistance in High-Risk Solid Tumors.
    Nguyen F; Guan P; Guerrero DT; Kolla V; Naraparaju K; Perry LM; Soberman D; Pressly BB; Alferiev IS; Chorny M; Brodeur GM
    Cancer Res; 2020 Oct; 80(19):4258-4265. PubMed ID: 32839252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Poloxamer-linked prodrug of a topoisomerase I inhibitor SN22 shows efficacy in models of high-risk neuroblastoma with primary and acquired chemoresistance.
    Alferiev IS; Guerrero DT; Guan P; Nguyen F; Kolla V; Soberman D; Pressly BB; Fishbein I; Brodeur GM; Chorny M
    FASEB J; 2022 Mar; 36(3):e22213. PubMed ID: 35192728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanocarrier-Based Delivery of SN22 as a Tocopheryl Oxamate Prodrug Achieves Rapid Tumor Regression and Extends Survival in High-Risk Neuroblastoma Models.
    Alferiev IS; Guerrero DT; Soberman D; Guan P; Nguyen F; Kolla V; Fishbein I; Pressly BB; Brodeur GM; Chorny M
    Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanoparticle delivery of an SN38 conjugate is more effective than irinotecan in a mouse model of neuroblastoma.
    Iyer R; Croucher JL; Chorny M; Mangino JL; Alferiev IS; Levy RJ; Kolla V; Brodeur GM
    Cancer Lett; 2015 May; 360(2):205-12. PubMed ID: 25684664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced Intratumoral Delivery of SN38 as a Tocopherol Oxyacetate Prodrug Using Nanoparticles in a Neuroblastoma Xenograft Model.
    Nguyen F; Alferiev I; Guan P; Guerrero DT; Kolla V; Moorthy GS; Chorny M; Brodeur GM
    Clin Cancer Res; 2018 Jun; 24(11):2585-2593. PubMed ID: 29514842
    [No Abstract]   [Full Text] [Related]  

  • 6. A nanotherapeutic strategy to overcome chemoresistance to irinotecan/7-ethyl-10-hydroxy-camptothecin in colorectal cancer.
    Huang Q; Liu X; Wang H; Liu X; Zhang Q; Li K; Chen Y; Zhu Q; Shen Y; Sui M
    Acta Biomater; 2022 Jan; 137():262-275. PubMed ID: 34718178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Camptothecin delivery systems: enhanced efficacy and tumor accumulation of camptothecin following its conjugation to polyethylene glycol via a glycine linker.
    Conover CD; Greenwald RB; Pendri A; Gilbert CW; Shum KL
    Cancer Chemother Pharmacol; 1998; 42(5):407-14. PubMed ID: 9771956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a camptothecin-11-refractory model.
    Sapra P; Zhao H; Mehlig M; Malaby J; Kraft P; Longley C; Greenberger LM; Horak ID
    Clin Cancer Res; 2008 Mar; 14(6):1888-96. PubMed ID: 18347192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prodrug and nanomedicine approaches for the delivery of the camptothecin analogue SN38.
    Bala V; Rao S; Boyd BJ; Prestidge CA
    J Control Release; 2013 Nov; 172(1):48-61. PubMed ID: 23928356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Camptothecin delivery systems: the utility of amino acid spacers for the conjugation of camptothecin with polyethylene glycol to create prodrugs.
    Conover CD; Greenwald RB; Pendri A; Shum KL
    Anticancer Drug Des; 1999 Dec; 14(6):499-506. PubMed ID: 10834271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PLK1 is a critical determinant of tumor cell sensitivity to CPT11 and its inhibition enhances the drug antitumor efficacy in squamous cell carcinoma models sensitive and resistant to camptothecins.
    Zuco V; De Cesare M; Zaffaroni N; Lanzi C; Cassinelli G
    Oncotarget; 2015 Apr; 6(11):8736-49. PubMed ID: 25826089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual 7-ethyl-10-hydroxycamptothecin conjugated phospholipid prodrug assembled liposomes with in vitro anticancer effects.
    Du Y; Zhang W; He R; Ismail M; Ling L; Yao C; Fu Z; Li X
    Bioorg Med Chem; 2017 Jun; 25(12):3247-3258. PubMed ID: 28465086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor regression and curability of preclinical neuroblastoma models by PEGylated SN38 (EZN-2208), a novel topoisomerase I inhibitor.
    Pastorino F; Loi M; Sapra P; Becherini P; Cilli M; Emionite L; Ribatti D; Greenberger LM; Horak ID; Ponzoni M
    Clin Cancer Res; 2010 Oct; 16(19):4809-21. PubMed ID: 20702613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel SN38 conjugate-forming nanoparticles as anticancer prodrug: in vitro and in vivo studies.
    Zhang H; Wang J; Mao W; Huang J; Wu X; Shen Y; Sui M
    J Control Release; 2013 Mar; 166(2):147-58. PubMed ID: 23266448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrating a novel SN38 prodrug into the PEGylated liposomal system as a robust platform for efficient cancer therapy in solid tumors.
    Fang T; Dong Y; Zhang X; Xie K; Lin L; Wang H
    Int J Pharm; 2016 Oct; 512(1):39-48. PubMed ID: 27544846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pulmonary targeting microparticulate camptothecin delivery system: anticancer evaluation in a rat orthotopic lung cancer model.
    Chao P; Deshmukh M; Kutscher HL; Gao D; Rajan SS; Hu P; Laskin DL; Stein S; Sinko PJ
    Anticancer Drugs; 2010 Jan; 21(1):65-76. PubMed ID: 19966540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Irinotecan overcomes the resistance to 5-fluorouracil in human colon cancer xenografts by down-regulation of intratumoral thymidylate synthase.
    Fukushima M; Sakamoto K; Ohshimo H; Nakagawa F; Taguchi T
    Oncol Rep; 2010 Oct; 24(4):835-42. PubMed ID: 20811661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamic core crosslinked camptothecin prodrug micelles with reduction sensitivity and boronic acid-mediated enhanced endocytosis: An intelligent tumor-targeted delivery nanoplatform.
    Huang Y; Zhang W; Xu Y; Zhu S; Wu Y; Chen T; Xiao Y; Lu W; Zhang X; Yu J
    Int J Pharm; 2020 Apr; 580():119250. PubMed ID: 32209369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of two self-assembled macromolecular prodrug micelles with different conjugate positions of SN38 for enhancing antitumor activity.
    Liu Y; Piao H; Gao Y; Xu C; Tian Y; Wang L; Liu J; Tang B; Zou M; Cheng G
    Int J Nanomedicine; 2015; 10():2295-311. PubMed ID: 25848251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transformative Nanomedicine of an Amphiphilic Camptothecin Prodrug for Long Circulation and High Tumor Uptake in Cancer Therapy.
    Zhang F; Zhu G; Jacobson O; Liu Y; Chen K; Yu G; Ni Q; Fan J; Yang Z; Xu F; Fu X; Wang Z; Ma Y; Niu G; Zhao X; Chen X
    ACS Nano; 2017 Sep; 11(9):8838-8848. PubMed ID: 28858467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.